Stocks-TXG-10X Genomics Inc

TXG 10X Genomics Inc

48.65 0.62 (1.29%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Overview

Prev Close48.65
Day's Range 46.84 - 48.70
52 Week Range 23.76 - 99.72
Average Volume (3M)1.35M
1-Year Return-44.34%
Beta1.1642
Market Cap5.57B
P/E Ratio
Revenue503.71M
EPS-1.4752
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.715/08/202226/10/202209/01/202325.0030.0035.0040.0045.0050.00
Chart times in UTC
Industry Biotechnology
CEO Serge Saxonov, PhD
Employees 1,239

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: 10X Genomics Inc's revenues increased by 64.13% and amounted to 490.49M. Net income increased by 89.27% to -58.22M. Net assets increased by 10.62% to 817.57M and EPS increased from -5.37 to -0.53.
TXG's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
75.42%
Net Profit Margin
-70.77%
Operating Margin
-31.90%
Return On Investment
-78.14%
12/21
03/22
06/22
09/22
Total Revenue
143.53M
114.5M
114.61M
131.07M
Gross Profit
115.93M
89.02M
86.91M
100.7M
Operating Income
-15.83M
-41.74M
-63.12M
-40M
Net Income
-18.45M
-42.41M
-64.46M
-41.91M